Label: information for the user
CELSENTRI 25mg film-coated tablets
CELSENTRI 75mg film-coated tablets
CELSENTRI 150mg film-coated tablets
CELSENTRI 300mg film-coated tablets
maraviroc
Read this label carefully before starting to take this medicine, because it contains important information for you.
CELSENTRI contains an active ingredient called maraviroc. Maraviroc belongs to a group of medicines calledantagonistsof the CCR5. CELSENTRI acts by blocking the receptor called CCR5, which HIV uses to enter and infect blood cells.
CELSENTRI is used to treat Human Immunodeficiency Virus type 1 (HIV-1) infection in adults, adolescents, and children aged 2 years and older, who weigh at least 10 kg.
CELSENTRI must be taken in combination with other medicines that are also used to treat HIV infection. All these medicines are referred to asantiretroviralorantiretroviralmedicines.
CELSENTRI, as part of the combined treatment, reduces the amount of virus in your body and keeps it at a low level. This helps your body to increase the count of CD4 cells in the blood. CD4 cells are a type of white blood cell that are important in helping your body to fight off infections.
Do not take CELSENTRI
Warnings and precautions
Consult your doctor or pharmacist before taking or administering CELSENTRI.
Your doctor must collect blood samples to see if CELSENTRI is an appropriate treatment for you (or your child, if the patient).
Some people who take CELSENTRI have developed severe allergic reactions or skin reactions (see also “Severe adverse reactions”in section 4).
Before taking this medication, make sure your doctor knows if you (or your child) have or have had any of the following problems:
Conditions to be aware of
Some people taking HIV medications develop other conditions, which can be serious. These include:
You need to know what important signs and symptoms to watch for while taking CELSENTRI.
Older patients
Only a limited number of people 65 years or older have taken CELSENTRI. If you belong to this age group, consult your doctor to see if you can take CELSENTRI.
Children
The use of CELSENTRI has not been tested in children under 2 years or weighing less than 10 kg. Therefore, CELSENTRI is not recommended for children under 2 years or weighing less than 10 kg.
Other medications and CELSENTRI
Inform your doctor or pharmacistif you (or your child)are taking,have taken recently, or may need to takeany other medication.
Inform your doctor or pharmacist if you (or your child) start taking a new medication while taking CELSENTRI.
It is likely that medications containing St. John's Wort (Hypericum perforatum) will prevent CELSENTRI from working correctly.Do not take it while taking CELSENTRI.
Some medications may affect CELSENTRI levels in the body when taken at the same time as CELSENTRI. These include:
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or intend to become pregnant:
The components of CELSENTRI are unknown to pass into breast milk. If you are breastfeeding or plan to breastfeed,you must consult your doctor as soon as possible.
Driving and operating machinery
CELSENTRI may make you feel dizzy.
CELSENTRIcontains soy lecithin and sodium.
Do not take this medication if you are allergic to peanuts or soy.
CELSENTRI contains less than 1 mmol of sodium (23 mg) in each tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor.This medicationindicated by your doctor.In case of doubt, consultyour doctor or pharmacist.
If you (or your child) are unable to swallow the tablets, your doctor will consider whether it is better for you to take the oral solution of CELSENTRI.
How much to take
Adults
The recommended dose of CELSENTRI is 150 mg, 300 mg, or 600 mg twice a daydepending on whether you are taking other medications at the same time.Always take the dose recommended by your doctor.
People with kidney problems
If you have kidney problems, your doctor may modify your dose.
Adolescents and children 2 years of age and older and weighing at least 10 kg
Your doctor will indicate the correct dose of CELSENTRI based on your weight and other medications you are taking at the same time.
CELSENTRI can be taken with or without food.CELSENTRI must always be taken orally.
CELSENTRI should be taken in combination with other medications used to treat HIV. Consult the package insert for these other medications to know how to take them.
If you take or administer more CELSENTRI than you should
If you accidentally take or administer too much CELSENTRI
If you forgot to take or administer CELSENTRI
If you (or your child) forgot to take or administer a dose of CELSENTRI, take it or administer it as soon as possible and continuewith the next dose at the usual time.
If it is almost time for the next dose, do not take or administer the missed dose. Wait to take the next dose at the time it is due.
Do not take or administer a double dose to make up for the missed doses.
If you (or your child) interrupt treatment with CELSENTRI
Continue treatment with CELSENTRI until your doctor tells you to.
It is essential that you take your medications every day at the time they are due, as this ensures that the HIV infection does not spread through your body. Unless your doctor tells you to stop treatment, it is essential thatyou (or your child) continuetreatment with CELSENTRI, as described above.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, CELSENTRI can cause side effects, although not everyone will experience them. Inform your doctor about any unusual changes in your health or your child's health.
Severe side effects - seek medical help immediately
Severe allergic or skin reactions
Some people taking CELSENTRI have developed severe skin reactions and potentially life-threatening allergic reactions. These are rare and may affectup to 1 in 1,000 peoplewho take CELSENTRI.
If you experience any of these symptoms while being treated with CELSENTRI:
Liver problems
These are rare and may affectup to 1 in 1,000 peoplewho take CELSENTRI.
The signs include:
Other side effects
Frequent side effects
These may affectup to 1 in 10 people:
Rare side effects
These may affectup to 1 in 100 people:
Very rare side effects
These may affectup to 1 in 1,000 people:
Other possible side effects of combined antiretroviral therapy for HIV
People taking combined antiretroviral therapy for HIV may develop other side effects.
Symptoms of infection and inflammation
People with advanced HIV infection (AIDS) have a weakened immune system and are more likely to develop serious infections (opportunistic infections). After starting treatment, the immune system becomes stronger, and the body begins to fight these infections.
These may developsymptoms of infection and inflammation,caused either by:
The symptoms of autoimmune disordersmay appear many monthsafter starting treatment with HIV medicines. The symptoms may include:
If you experience any symptoms of infection or if you notice any of the above symptoms:
Joint pain, stiffness, and bone problems
Some patients taking combined antiretroviral therapy for HIV develop a condition calledosteonecrosis. In this condition, parts of the bone tissue die due to reduced blood supply to the bones.
The frequency of this condition is unknown. It is more likely to develop:
The signs to watch out for include:
If you notice any of these symptoms:
Reporting side effects
If you experienceany type ofside effect, consult your doctor or pharmacist,even if it is apossibleside effect that does not appear in this leaflet.You can also report them directly through thenational reporting system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use CELSENTRI after the expiration date that appears on the box, blister pack, or bottle label. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medicines you no longer need. This will help protect the environment.
Composition of CELSENTRI
Core of the tablet:microcrystalline cellulose, anhydrous calcium hydrogen phosphate, sodium glycolate starch, magnesium stearate.
Coating:poly(vinyl alcohol), titanium dioxide (E171), macrogol 3350, talc, soy lecithin, aluminium lake of indigo carmine (E132).
Appearance of the product and contents of the pack
The film-coated tablets of CELSENTRI are blue and engraved with "MVC 25", "MVC 75", "MVC 150" or "MVC 300".
CELSENTRI 25 mg and 75 mg film-coated tablets are supplied in bottles of 120 tablets.
CELSENTRI 150 mg and 300 mg film-coated tablets are supplied in bottles of 60 tablets or in blisters of 30, 60 or 90 film-coated tablets and in multiple packs containing 180 (2 packs of 90) film-coated tablets.
Only some pack sizes may be marketed.
Marketing authorisation holder:
ViiV Healthcare BV,Van Asch van Wijckstraat 55H,3811 LP Amersfoort, Netherlands.
Manufacturer responsible:
Pfizer Manufacturing DeutschlandGmbH, Mooswaldallee 1, 79108 Freiburg Im Breisgau, Germany.
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel: + 32 (0)10 85 65 00 | Lietuva ViiV Healthcare BV Tel: +370 80000334 |
Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel: + 32 (0)10 85 65 00 | |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 | Magyarország ViiV Healthcare BV Tel.: +36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 | Malta ViiV Healthcare BV Tel: +356 80065004 |
Deutschland ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 | Nederland ViiV Healthcare BV Tel: + 31 (0)33 2081199 |
Eesti ViiV Healthcare BV Tel: +372 8002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλáδα GlaxoSmithKlineΜονοπρóσωπηA.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 |
España Laboratorios ViiV Healthcare, S.L. Tel: + 34900 923 501 | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél.: + 33 (0)1 39 17 6969 | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA. Tel: + 351 21 094 08 01 |
Hrvatska ViiV Healthcare BV Tel: +385 800787089 | România ViiV Healthcare BV Tel: +40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel: +386 80688869 |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika ViiV Healthcare BV Tel: +421 800500589 |
Italia ViiV Healthcare S.r.l. Tel: + 39 (0)45 7741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κúπρος ViiV Healthcare BV Τηλ: +357 80070017 | Sverige GlaxoSmithKline AB Tel:+ 46 (0)8 638 93 00 |
Latvija ViiV Healthcare BV Tel: +371 80205045 |
Last update of this leaflet: {MM/YYYY}
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.